Nakano et al. developed a PIM3 inhibitor (Compound 11) using PIM1’s crystal structure as a surrogate to offer a foundation for rational drug design and showed that inhibition of PIM3 kinase activity reduced the proliferation of various pancreatic cancer cell lines. This evidence concerns the gene PIM1 and pancreatic neoplasm.